

Neurologia Croatica

SINCE 1953

Contents / Sadržaj

ORIGINAL SCIENTIFIC PAPER / IZVORNI ZNANSTVENI RAD

- 3 | **Efficacy of carbamazepine and oxcarbazepine co-administration in the treatment of epilepsy**
(Učinkovitost istodobne primjene karbamazepina i okskarbazepina u liječenju epilepsije)
Sanja Hajnšek, Vlatko Šulentić, Ivana Čajić, Željka Petelin Gadže, Sibila Nanković, Zdravka Poljaković, Magdalena Krbot Skorić, Andreja Bujan Kovač, Filip Đerke

CASE REPORT / PRIKAZ BOLESNIKA

- 11 | **Ganglionic nAChR antibody positive autoimmune autonomic ganglionopathy with spontaneous recovery**
(Autoimuna autonomna ganglionopatija pozitivna na ganglionska nAChR protutijela sa spontanim oporavkom)
Ivan Adamec, Luka Crnošija, Magdalena Krbot Skorić, Ervina Bilić, Mario Habek
- 15 | **SUBJECTS AND AUTHORS INDEX FOR VOLUME 67/2018**
PREDMETNO I AUTORSKO KAZALO ZA VOLUMEN 67/2018.
- 19 | **INSTRUCTIONS TO AUTHORS**
UPUTE AUTORIMA

INDEXED / ABSTRACTED IN

Science Citation Index Expanded

SCOPUS

NEUROLOGIA CROATICA (Vol. 1-24 "Neuropsihijatrija", Vol. 25-39 "Neurologija") Journal of Clinical Neuroscience published by University Department of Neurology, Zagreb University Hospital Center, School of Medicine, University of Zagreb, Zagreb, Republic of Croatia

NEUROLOGIA CROATICA (Vol. 1-24 "Neuropsihijatrija", Vol. 25-39 "Neurologija") Časopis kliničkih neuroznanosti izdaje Neurološka klinika, Klinički bolnički centar Zagreb, Medicinski fakultet Sveučilišta u Zagrebu, Zagreb, Republika Hrvatska

EDITORIAL BOARD – UREDNIČKI ODBOR

Editor-in-Chief / Glavna urednica:

S. Hajnšek

Associate editors / Pridruženi urednici:

D. Petravić, Z. Poljaković

Assistant editors / Pomoćnici urednika:

Ž. Petelin Gadže, M. Habek, E. Bilić, D. Mahović Lakušić, A. Bazina, A. Bujan Kovač, I. Adamec, M. Krbot Skorić, K. I. Tudor, T. Gabelić

Members / Članovi:

I. Barić

N. Barišić

B. Baršić

M. Bošnjak Pašić

V. Brinar

G. Buljat

B. Cerovski

D. Chudy

I. Lušić

B. Malojčić

Z. Mitrović

Z. Mubrin

V. Neseck Mađarić

J. Paladino

G. Pavliša

M. Radoš

M. Relja

K. Rotim

Ž. Vogrinc

M. Žagar

Book review editor / Urednik za prikaze knjiga:

S. Telarović

Technical editor / Tehnički urednik:

D. Beritić-Stahuljak

Croatian Language Editor/Lektor za hrvatski jezik:

D. Beritić-Stahuljak

English Language Editor/Lektor za engleski jezik:

A. Redovniković

Manager editor / Financijsko-administrativni poslovi:

A. Bujan Kovač

Printed and typesetting by / Tisak i dizajn:

DENONA d.o.o., Getaldićeva 1, Zagreb

ADVISORY BOARD – SAVJETODAVNI ZNANSTVENI UREDNIČKI ODBOR

I. Antončić, Rijeka

J. Antel, Montreal

S. Apostolski, Beograd

N. Bogdanović, Stockholm

F. Borovečki, Zagreb

H. Budka, Vienna

A. Danek, Munich

V. Deletis, Split

M. Dikšić, Montreal

M. Dimitrijević, Houston

M. Judaš, Zagreb

L. Kappos, Basel

A. Korczyn, Tel Aviv

I. Kostović, Zagreb

D. Leppert, Basel

C. Mounayer, Limoges

Z. Pirtošek, Ljubljana

P. Rakić, New Haven

D. Schmidt, Berlin

J. Sertić, Zagreb

O. Sinanović, Tuzla

G. J. Spilich, Chestertown

V. Švigelj, Ljubljana

W. K. Tang, Hong Kong

E. Trinkka, Salzburg

P. Vermersch, Lille

A. Vincent, Oxford

S. Vukušić, Lyon

J. Wellmer, Bochum

J. Zidar, Ljubljana

K. Žarković, Zagreb

Neurologia Croatica

SINCE 1953

OFFICIAL JOURNAL OF

Croatian Neurological Society
Croatian Neurosurgical Society

INDEXED / ABSTRACTED IN

Science Citation Index Expanded
SCOPUS
Bowker Int. Series Data Base

SLUŽBENI ČASOPIS

Hrvatskoga neurološkog društva
Hrvatskoga neurokirurškog društva

INDEKSIRAN / CITIRAN

Science Citation Index Expanded
SCOPUS
Bowker Int. Series Data Base

FORMER EDITORS
/ PRETHODNI UREDNICI

† Z. Novak	1953 – 1982
S. Knežević	1983 – 1989
† D. Jadro-Šantel	1990 – 1993
Z. Mubrin	1994 – 1996
N. Zurak	1996 – 2005
V. Brinar	2005 – 2006

NEUROLOGIA CROATICA is published twice a year.

All correspondence including books for review should be addressed to:

NEUROLOGIA CROATICA,
University of Zagreb, School of Medicine and Zagreb
University Hospital Center, University Department of
Neurology, Kišpatićeva 12, HR-10 000 Zagreb, Croatia;
phone/fax: +385 1 2388 176.
E-mail: neurologiacroatica@kbc-zagreb.hr
Web address: www.neurologiacroatica.com

Subscription rate: an annual volume in Croatia is 100 HRK for individuals and 200 HRK for institutions, payable to the account No. 2503007-1100007828, SPES - Društvo za pomoć neurološkim bolesnicima, KBC Zagreb, Kišpatićeva 12, 10 000 Zagreb. All other countries: 30 USD for individuals and 50 USD for institutions, payable to the account No. SWIFT VBCRHR22-4082867101, Volksbank d.d., 10 000 Zagreb, Croatia.

Ministry of Science, Education and Sports, Republic of Croatia supports regular printing of the journal.


NEUROLOGIA CROATICA izlazi dva puta na godinu.

Svu korespondenciju uključujući knjige za rubriku *Prikaz knjige* molimo poslati na sljedeću adresu:

NEUROLOGIA CROATICA,
Klinika za neurologiju,
Klinički bolnički centar Zagreb,
Kišpatićeva 12, 10 000 Zagreb;
tel/faks: 01 2388 176.
E-mail: neurologiacroatica@kbc-zagreb.hr
Web adresa: www.neurologiacroatica.com

Godišnja pretplata u Hrvatskoj iznosi 100 kn za pretplatnike pojedince i 200 kn za ustanove, uplata na žiro račun broj 2503007-1100007828, SPES - Društvo za pomoć neurološkim bolesnicima, KBC Zagreb, Kišpatićeva 12, 10 000 Zagreb. Za sve ostale zemlje godišnja pretplata iznosi 30 USD za pojedince pretplatnike i 50 USD za ustanove, uplata na račun broj SWIFT VBCRHR22-4082867101, Volksbank d.d., 10 000 Zagreb, Hrvatska.

Ministarstvo znanosti, obrazovanja i sporta Republike Hrvatske podupire tiskanje časopisa.



Efficacy of carbamazepine and oxcarbazepine co-administration in the treatment of epilepsy

Sanja Hajnšek¹, Vlatko Šulentić¹, Ivana Čajić¹, Željka Petelin Gadže¹, Sibila Nanković¹, Zdravka Poljaković¹, Magdalena Krbot Skorić¹, Andreja Bujan Kovač¹, Filip Đerke²

ABSTRACT – Objectives: Carbamazepine (CBZ) and oxcarbazepine (OXC) are first-line antiepileptic drugs (AEDs) for partial and generalized seizures with focal onset. However, from the pharmacodynamic and pharmacokinetic point of view, CBZ and OXC are not identical medications. As CBZ and OXC nonetheless differ, their co-administration should be considered in pharmaco-resistant patients. **Methods:** We performed a retrospective study with the aim to determine the efficacy of concurrent administration of CBZ and OXC in the treatment of pharmaco-resistant patients with partial epilepsy. The study included 24 patients in whom former a combination of other first- and second-line AEDs for partial seizures had been ineffective. The mean follow up time was 23.50 ± 8.81 months. The majority (72.9%) of patients had symptomatic epilepsy and the mean disease duration was 22.29 ± 15.30 years. The efficacy was estimated 6 months after therapy introduction. **Results:** The number of seizures before combined CBZ + OXC therapy introduction was higher (8.47 ± 8.52) compared to the number of seizures after therapy introduction (4.49 ± 5.44) and the difference was statistically significant ($p=0.015$). The combination of OXC and CBZ yielded improvement. Reduction of seizures (25%-99%) was recorded in 50% of patients. Clinically significant seizure reduction by $\geq 50\%$ was observed in 29.17% of patients. The most common side effects were drowsiness, vertigo and hyponatremia, which was not clinically significant. **Conclusions:** Our study demonstrated the efficacy of combined CBZ and OXC therapy, notably in pharmaco-resistant partial epilepsy, with recommendation of using lower doses, which leads to better tolerance and avoidance of adverse effects.

Key words: carbamazepine, oxcarbazepine, epilepsy, pharmaco-resistance

¹ Zagreb University Hospital Centre, School of Medicine, University of Zagreb, Department of Neurology, Referral Centre for Epilepsy of the Ministry of Health of the Republic of Croatia, Zagreb, Croatia

² Student, School of Medicine, University of Zagreb, Zagreb, Croatia

INTRODUCTION

Carbamazepine (CBZ) and oxcarbazepine (OXC) are first-line antiepileptic drugs (AEDs) for partial and generalized seizures with focal onset. However, from the pharmacodynamic and pharmacokinetic point of view, CBZ and OXC are not identical medications. Carbamazepine (CBZ) is an iminodibenzyl derivative (10,11-dihydro 5H-dibenzo(b,f)azepine). The mechanism of action of CBZ is based on binding to voltage-dependent sodium channels, both pre- and post-synaptic, causing channel blocking and blockage of high-frequency discharges and excitatory transmission. The main metabolic pathway is first epoxidation in carbamazepine 10,11-epoxide, then hydrolysis in carbamazepine 10,11-trans-dihydrodiol, followed by glucuronidation and sulfuration. The main path of epoxidation is *via* cytochrome P450 CYP3A4. During treatment, some adverse effects can occur in 30%-50% of patients treated with CBZ, however, these are mostly mild, not requiring therapy interruption. However, about 5% of patients must cease therapy due to severe adverse effects. Most frequent adverse effects are drowsiness, general fatigue, dizziness, ataxia, diplopia, sedation, insomnia, tremor, impotence, leucopenia, hyponatremia, rash and other skin reactions (including Stevens-Johnson and Lyell syndromes) (1,2).

Oxcarbazepine is a 10-keto derivative of carbamazepine (10,11-dihydro-10-oxo-5H-dibenzo(b,f)azepine-5-carboxamide). Pharmacological activity of OXC is exclusively through the main action metabolite 10-monohydroxy derivative (MHD). The main action mechanism is, as in CBZ, blockage of voltage-dependent sodium channels, which results in stabilization of neural membrane, inhibition of repeated neural discharges and prevention of discharge spreading. In contrast to CBZ, MHD amplifies potassium conductivity and modulates high voltage types of calcium channels. It acts similarly to CBZ upon NMDA receptors, but without greater impact upon serotonergic, GABA and acetylcholine receptors. In contrast to CBZ, OXC has no auto induction. OXC has actually emerged as the result of aimed search for structured variation of CBZ, all with the goal of eliminating epoxide CBZ metabolites responsible for the occurrence of most adverse effects. The elimination half-life is 8-10 hours (1-4). The main adverse effects of OXC are basically similar to those of CBZ. However, OXC is better tolerated when compared to standard CBZ formula, and in comparison with CR preparation did not show substantial differences. Discontinuation rate was still significantly lower for OXC com-

pared to CBZ (14%-26%). Regarding its role in add-on therapy in clinical studies, a higher frequency of cessation was found in higher doses of the drug, at percentages of 12%, 36% and 67% for the doses of 600, 1200 and 2400 mg, respectively (5). The main adverse affects are headache, dizziness, nausea, ataxia, diplopia and hyponatremia, and of the severe ones skin rash occurs in approximately 5% of cases, in comparison with 10%-15% for CBZ.

PATIENTS AND METHODS

At the Referral Centre for Epilepsy of the Ministry of Health of the Republic of Croatia at the Department of Neurology, Zagreb University Hospital Centre, we performed a retrospective study with the aim of determining the efficacy, optimum doses and tolerability of co-administration of CBZ and OXC in the treatment of pharmacoresistant patients with partial epilepsy with or without secondary generalization. Twenty-four patients in whom former administration of a combination of other first- and second-line AEDs for partial seizures had been ineffective were included in the study conducted during the 2009-2013 period. The follow up period was 6 to 37 months. The efficacy was estimated 6 months after therapy introduction. In the cases where the doses of drugs in the mentioned period were increased, additional follow up period was 3 months after dose correction. Statistical analysis was done by using the IBM SPSS Statistics 20 statistical package. Quantitative variables were expressed as arithmetic mean and standard deviation (SD). Qualitative variables were expressed as prevalence and percentage (%). Student's t-test was used for comparison among subunits for quantitative variables. The relation of individual variables that were partly qualitative and partly quantitative was evaluated by Spearman correlation coefficient (r_s). The probability value of $p=0.05$ was considered statistically significant.

An informed consent was obtained from all patients included in the study.


RESULTS

Twenty-four patients (15 male and 9 female) with pharmacoresistant partial epilepsy were included in the study, seven of them without and 17 with secondary generalized seizures. The majority ($n=19$; 72.9%) had symptomatic epilepsy. Considering seizure etiology, most of the patients had hippo-

campal sclerosis (n=6), followed by traumatic brain injury (n=5), arachnoidal cysts (n=2), tumors (n=2), stroke (n=2), focal cortical dysplasia (n=1) and perinatal vascular lesions (n=1) (Fig. 1). Some of the patients with positive brain magnetic resonance imaging (MRI) results were operated on after the follow up period. The results regarding clinical outcome following epilepsy surgery are beyond the scope of this article. The mean patient age was 40.96±14.99 years, mean duration of disease 22.29±15.30 years, and mean follow up period 23.50±8.81 months. The majority of patients (50%) had one additional AED besides the mentioned combination, 33.3% had another two AEDs, and 12.5% had three additional AEDs. Only one patient was administered exclusively the combination of CBZ and OXC. Additional AED mostly was

lamotrigine (LTG) (n=15), followed by valproate (VPA) (n=10) and methylphenobarbitone (MPB) (n=6). The mean CBZ dose was 750.00±284.37 mg, with the mean CBZ serum concentration of 26.55±10.65 µmol/L (therapeutic concentration 17-50 µmol/L). CBZ was in therapeutic range in 79.2% of patients (n=19), 12.5% of patients (n=3) had CBZ below therapeutic range, whereas 4.2% of patients (n=1) had CBZ slightly above therapeutic range. The mean dose of OXC was 1012.50±403.58 mg with the mean OXC serum concentration of 42.43±19.42 µmol/L (therapeutic concentration 24-140 µmol/L). In the majority of patients (79.2%; n=19), OXC was in therapeutic range, whereas in 20.8% (n=5) OXC was below therapeutic range.

The mean number of epileptic seizures *per* month before the introduction of combined CBZ + OXC therapy was 8.47±8.52 and the number of seizures *per* month after the introduction of the mentioned therapy was lower, 4.49±5.44 (Fig. 2). The difference was statistically significant (p=0.015). Comparison of the mean number of seizures before and after the introduction of dual therapy (OXC + CBZ) showed improvement. Significant reduction in the number of seizures was observed in 50% of patients (n=12); 20.83% (n=5) of them had minimal improvement, i.e. 25%-49% seizure reduction. In 16.67% of patients (n=4), there was 50%-74% seizure reduction, whereas 12.50% of patients (n=3) had ≥75% seizure reduction (Fig. 3). Clinically significant ≥50% seizure reduction was observed in 29.17% of patients (n=7). There was no aggravation of seizures in any patient. The median of improvement was 22.50%.



HS – hippocampal sclerosis; TBI – traumatic brain injury; AC – arachnoidal cyst; TM – tumor; CVI – cerebrovascular insult; FCD – focal cortical dysplasia; PVL – perinatal vascular lesions

Fig. 1. Patient distribution according to etiology.




Fig. 2. The number of seizures per month (0-30) before the introduction of CBZ + OXC therapy was higher compared to the number of seizures after therapy introduction; the difference was statistically significant (p=0.015).




Fig. 3. Patients divided into groups according to outcome; total reduction in the number of seizures by 25%-99% was observed in 50% ($n=12$) of patients.




Fig. 4. Statistically significant correlation between total improvement (%) and OXC dose (mg) ($r_s=0.546$; $p=0.006$).

The following adverse effects were recorded: drowsiness ($n=4$), vertigo ($n=3$), hyponatremia ($n=3$), with a note that the lowest Na value was 121 mmol/L, then diplopia ($n=2$), vision disturbances ($n=1$), nausea and vomiting ($n=1$). In three patients, adverse effects disappeared upon decreasing the dose of one of the drugs. Therapy was ceased in 41.70% of patients ($n=10$), in 29.2% ($n=7$) of them due to inefficacy, in 8.3% ($n=2$) due to adverse effects, whereas in 4.2% ($n=1$) there was no clear cause (non-compliance); 58.3% of patients ($n=14$) continued to take combined CBZ + OXC therapy.

On comparing the two groups of patients regarding seizure types, i.e. the group with partial seizures with secondary generalization and the group with partial seizures without secondary generalization, there was no statistically significant difference in the treatment outcome. There was no statistically significant difference in the outcome regarding seizure etiology, i.e. whether it was cryptogenic or symptomatic epilepsy, either. When compared whether there was more significant improvement if LTG was added to the mentioned CBZ + OXC combination ($n=15$), no statistically significant difference was found. However, a correlation was

found between overall outcome and OXC dose, i.e. the higher the OXC dose, the better was seizure reduction ($r_s=0.546$; $p=0.006$) (Fig. 4). There was no statistically significant correlation between overall outcome and CBZ dose ($r_s=-0.215$; $p=0.312$).

DISCUSSION AND CONCLUSION

From the pharmacodynamic point of view, CBZ and OXC are not identical medications (6). CBZ binds doubly to plasma proteins than the active OXC metabolite MHD, so OXC is a more effective drug. In contrast to CBZ that oxidizes *via* cytochrome P-450 system, OXC yields to reduction metabolism of MHD that is glucuronidated and extracted through urine. The influence of liver cytochrome P-450 upon OXC metabolism is minimal. This explains why the combination with other AEDs, e.g., VPA, could be more efficacious, i.e. why the combined administration of OXC and CBZ should be effective. CBZ has a shorter elimination half-life, particularly when combined with other enzyme inducing AEDs, which can cause significant fluctuation of CBZ serum concentration and the occurrence of adverse effects. Daily fluctuation of MHD concentration is relatively low, lower than expected regarding the half-life of MHD elimination, with the note that relatively large fluctuations can be seen in some patients. The OXC concentration is much less affected by some other conventional AEDs such as VPA, phenobarbitone (PB) and phenytoin (PHT). Therefore, the oscillation in concentrations of OXC and its metabolite MHD is much less expressed than in CBZ (7). Thus, instead of increasing the CBZ dose, it would be justified to add lower OXC doses.

Oxcarbazepine is used in monotherapy for all types of partial seizures with or without secondary generalizations, as well as in add-on therapy. Also, OXC proved to be the optimal therapeutic choice in patients with refractory partial epilepsy, where seizure reduction by 27%-29% was achieved at the minimal OXC dose of 1200 mg (5,8). Add-on therapy with OXC in pharmacoresistant epilepsies brought to seizure reduction, by more than 50% in 20%-50% of patients, and was dose dependent. At the dose of 600 mg, the seizure reduction by 27% was achieved, at the dose of 1200 mg it was 41%, and at the dose of 2400 mg it was 50%. Adverse effects were also dose dependent, so that the percentage of adverse effects ranged from 91% to 72% at the dose of 2400 mg, 90% to 76% at the dose of 1200 mg, and without substantial difference in adverse effects at the drug dose of 600 mg. This indi-

cates that drug adverse effects are more pronounced at higher doses (5).

As it has been undoubtedly proven that the adverse effects of CBZ and OXC administration are dose dependent and more pronounced in higher doses of both AEDs, and there are evident differences in the action mechanisms of both drugs, it seems reasonable to consider co-administration of both drugs at somewhat lower individual doses.

As CBZ is extensively metabolized through the liver, it could be hepatotoxic. These adverse effects could be diminished and avoided by lowering the CBZ dose and adding OXC that is not hepatotoxic. This is particularly important in elderly patients with reduced liver function who also take some potentially hepatotoxic medications (statins, non-steroidal antirheumatics).

A relatively frequent adverse effect of OXC (but less common in CBZ) is hyponatremia. A study including 75 patients with normal sodium levels at the onset of OXC therapy showed that 26% of patients had mild decrease in sodium levels. A more pronounced decrease under 125 mmol/L was recorded in 2.6% of patients, whereas 1.3% had symptomatic lowering (9). The mechanism of hyponatremia occurrence is possibly a sequel of inappropriate antidiuretic hormone secretion (10). Some investigations suggest that it may be a direct impact of OXC on renal tubules, with the occurrence of reduced excretion of free water leading to relative drop of sodium concentration (11). In younger patients, no clear correlation of hyponatremia, age, concomitant use of other drugs, serum concentration of active substance and OXC dose was found (10,11). In adults and elderly persons, hyponatremia is related to dose, possibly due to weakened renal function that can cause more expressed hyponatremia at a higher drug level, particularly if the patient concomitantly takes medications such as diuretics, antidepressants or non-steroidal antirheumatics (12). Thus, in case of hyponatremia, the OXC dose should be lowered along with the addition of a lower CBZ dose with the aim of achieving satisfactory therapeutic effect.

Carbamazepine and OXC have shown poorer efficacy in the treatment of older people, taking into account seizure reduction and drug withdrawal during the study due to adverse effects and inefficacy. In elderly, the half-life of drug elimination is longer. CBZ clearance is lower, so smaller doses are required. Sedative effect of a drug can diminish its tolerability, thus therapy should be commenced with a very low dose (100 mg/day) and titrated up

to the total of 400 mg/day, divided into two daily doses (13). As OXC does not lead to the occurrence of epoxide metabolites responsible for the majority of CBZ adverse effects, it has been proven safe for use in elderly patients. Also, it is recommended to start with a low dose with gradual increase to 600 mg/day divided in two daily doses, which can be raised in case of clinical indication. Among adverse effects in elderly people, a higher risk of hyponatremia has been observed with the concurrent use of diuretics, followed by skin rash, nausea, vertigo and vomiting. CBZ as the cell membrane stabilizer increases the risk of cardiac arrhythmia, and its anticholinergic effect can precipitate urinary retention. It is possible that the OXC and CBZ combination could also give better results in this indication with lower individual doses of both AEDs causing fewer adverse effects.

Along with the impact on voltage dependent sodium channels, CBZ and OXC can block neuronal nicotine receptors. Due to this capacity, they can be used in the treatment of autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE). ADNFLE is an autosomal dominant disorder for which two genes have been identified, CHRNA4 and CHRNB2 that code neuronal nicotine acetylcholine receptor $\alpha 4$ and $\beta 2$ subunits. CBZ inhibits $\alpha 4\beta 2$, $\alpha 2\beta 2$ and $\alpha 2\beta 4$ receptors and thus achieves good effect upon neuronal nicotine receptors, but has various effects on particular subunits. OXC mostly affects $\alpha 4\beta 2$, if in therapeutic concentrations, and somewhat less $\alpha 2\beta 4$ subunit. As CBZ is the drug of first choice in the treatment of ADNFLE but proved ineffective in 30% of cases, probably because of different impact on individual subunits of nicotine acetylcholine receptors, as well as their variable expression in particular ADNFLE cases, co-administration of OXC and CBZ would make sense regarding specific blockage of individual subunits (14,15). By using the usual OXC doses, the appropriate concentration of MHD in cerebrospinal fluid for the inhibition of nicotine receptors is achieved. It could not be reached with CBZ without adverse effects related to higher drug doses.

Taking in account all the differences between CBZ and OXC, their mechanisms of actions and indications mentioned above, the question arises whether this combination would be more effective than the administration of each of these two AEDs alone, particularly in the treatment of pharmacoresistant epilepsies (16-21).

On review of the available literature, we found no studies that measured the efficacy of combined CBZ and OXC administration in reducing epilep-

tic seizures. Our study showed the mentioned combination to be justified, particularly in pharmacoresistant partial epilepsies with or without secondary generalization.

In our study, the combination of OXC and CBZ yielded improvement in 50% of patients (n=12), i.e. reduction of seizures by 25%-99%. Clinically significant seizure reduction by $\geq 50\%$ was observed in 29.17% of patients. There was no aggravation of seizures in any patient. It should be mentioned that these were mainly the cases of pharmacoresistant partial epilepsies with the average disease duration of 22 years, in whom former administration of a combination of other first- and second-line AEDs for partial seizures had been ineffective. Considering seizure etiology, most of the patients had hippocampal sclerosis (25%). There is the possibility that in non-pharmacoresistant patients even better efficacy could be achieved. The most common adverse effects were drowsiness, vertigo and hyponatremia that was not clinically significant. In 21.4% of patients side effects disappeared upon decreasing the dose of one of the drugs, whereas in only 8.3% of patients therapy was discontinued due to adverse effects. A statistically significant correlation was observed between the OXC dose and reduction of seizure number, i.e. the higher the OXC dose, the better efficacy was recorded. The average dose was 1012 mg. A somewhat higher dose would probably display even better efficacy, thus the recommendation may be to use the total OXC dose of 1200 mg (possibly up to 1500 mg), and in older groups 600-900 mg *per day*. The average CBZ dose was 750 mg, and the recommend total CBZ daily dose would be 600-800 mg, and 400 mg in the elderly. The introduction of drugs should be gradual, and in reaching the recommended doses monitoring serum concentration of both medications is advised.

As it is undoubtedly the issue of two AEDs with different action mechanism, their co-administration proved justified, particularly in some types of epilepsy. Our study also demonstrated the efficacy of combined CBZ and OXC therapy, notably in pharmacoresistant partial epilepsy, with the recommendation of using lower doses, which leads to better tolerability of both drugs.

REFERENCES

- Schmidt D, Schachter SC. Drug treatment of epilepsy in adults. *BMJ* 2014;348:g254. doi: 10.1136/bmj.g254
- Panayiotopoulos CP. Pharmacopoeia. In: Panayiotopoulos CP, ed. *Epileptic Syndromes and Their Treatment*. 2nd edn. London: Springer 2007: 505-50.
- Faught E. Oxcarbazepine. In: Shorvon S, Perucca E, Fish D, Dodson E, eds. *The Treatment of Epilepsy*. 2nd edn. Oxford: Blackwell 2004: 451-60.
- May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. *Clin Pharmacokinet* 2003;42(12):1023-42.
- Barcs G, Walker EB, Elger CE, *et al.* Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. *Epilepsia* 2000;41(12):1597-607.
- Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs. *Epilepsy Behav* 2004;5(5):627-35.
- May TW, Rambeck B, Salke-Kellermann A. Fluctuations of 10-hydroxycarbamazepine during the day in epileptic patients. *Acta Neurol Scand* 1996;93:393-7.
- Hajnšek S, Kovačević I, Petelin Ž. Epilepsy – therapeutic guidelines. *Neurol Croat* 2010;59(1-2):35-61.
- Holtmann M, Krause M, Opp J, Tokarzewski M, Korn-Merker E, Boenigk HE. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium – replacing carbamazepine with oxcarbazepine in children. *Neuropediatrics* 2002;33(6):298-300.
- Cilli AS, Algun E. Oxcarbazepine-induced syndrome of inappropriate secretion of antidiuretic hormone. *J Clin Psychiatry* 2002;63(8):742.
- Sachdeo RC, Wasserstein A, Mesenbrink PJ, D'Souza J. Effects of oxcarbazepine on sodium concentration and water handling. *Ann Neurol* 2002;51(5):613-20.
- Van Amelsvoort T, Bakshi R, Devaux CB, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. *Epilepsia* 1994;35(1):181-8.
- Curran HV, Java R. Memory and psychomotor effects of oxcarbazepine in healthy human volunteers. *Eur J Clin Pharmacol* 1993;44(6): 529-33.
- Di Resta C, Ambrosi P, Curia G, Becchetti A. Effect of carbamazepine and oxcarbazepine on wild-type and mutant neuronal nicotinic acetylcholine receptors linked to nocturnal frontal lobe epilepsy. *Eur J Pharmacol* 2010;643(1): 13-20.


15. Weltzin MM, Lindstrom JM, Lukas RJ, Whiteaker P. Distinctive effects of nicotinic receptor intracellular-loop mutations associated with nocturnal frontal lobe epilepsy. *Neuropharmacology* 10;102:158-73. doi: 10.1016/j.neuropharm.2015.11.004
16. Kwan P, Arzimanoglou A, Berg AT, *et al.* Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. *Epilepsia* 2010;51(6):1069-77.
17. Berg AT. Defining intractable epilepsy. *Adv Neurol* 2006;97:5-10.
18. Berg AT, Kelly MM. Defining intractability: comparisons among published definitions. *Epilepsia* 2006;47(2):431-6.
19. Loscher W. How to explain multidrug resistance in epilepsy? *Epilepsy Curr* 2005;5(3):107-12.
20. Kwan P, Brodie MJ. Potential role of drug transporters in the pathogenesis of medically intractable epilepsy. *Epilepsia* 2005;46(2):224-35.
21. Sisodiya SM, Lin WR, Harding BN, Squier MV, Thom M. Drug resistance in epilepsy: human epilepsy. *Novartis Found Symp* 2002;243:167-74; discussion 174-9.

Address for correspondence: Vlatko Šulentić, MD, MS, Zagreb University Hospital Centre, Department of Neurology, Referral Centre for Epilepsy of the Ministry of Health of the Republic of Croatia, Kišpatičeva 12, HR-10000 Zagreb, Croatia; E-mail: vlatko.sulentic@hotmail.com

Učinkovitost istodobne primjene karbamazepina i okskarbazepina u liječenju epilepsije

SAŽETAK – Cilj: Karbamazepin (CBZ) i okskarbazepin (OXC) su antiepileptici prvog izbora za parcijalne (žarišne) i generalizirane epileptične napadaje. Međutim, s farmakodinamskog i farmakokinetičkog stajališta CBZ i OXC nisu jednaki lijekovi. S obzirom na to da se CBZ i OXC ipak razlikuju, njihovu istodobnu primjenu treba razmotriti u slučaju farmakorezistentnih bolesnika. **Metode:** Proveli smo ovo retrospektivno istraživanje kako bismo utvrdili učinkovitost istodobne primjene CBZ i OXC u liječenju farmakorezistentnih bolesnika s parcijalnom epilepsijom. Istraživanje je obuhvatilo 24 bolesnika kod kojih se prethodna kombinacija antiepileptika prvog i drugog izbora za parcijalne epileptične napadaje pokazala neučinkovitom. Srednje vrijeme praćenja bilo je $23,50 \pm 8,81$ mjeseci. Većina bolesnika (72,9 %) imala je simptomatičnu epilepsiju, a srednje trajanje bolesti bilo je $22,29 \pm 15,30$ godina. Učinkovitost liječenja procijenjena je 6 mjeseci od uvođenja terapije. **Rezultati:** Broj napadaja prije uvođenja kombinirane terapije lijekovima CBZ i OXC bio je viši ($8,47 \pm 8,52$) u usporedbi s njihovim brojem nakon uvođenja ove terapije ($4,49 \pm 5,44$), a razlika je bila statistički značajna ($p=0,0159$). Kombinacija lijekova OXC i CBZ rezultirala je poboljšanjem. Smanjenje napadaja (25%-99 %) zabilježeno je u 50 % bolesnika. Klinički značajno smanjenje napadaja za ≥ 50 % utvrđeno je u 29,17 % bolesnika. Najčešće nuspojave bile su pospanost, vrtoglavica i hiponatremija, ali nisu bile klinički značajne. **Zaključak:** Naše istraživanje je pokazalo učinkovitost kombinirane terapije lijekovima CBZ i OXC, osobito kod farmakorezistentne parcijalne epilepsije, uz preporuku davanja nižih doza koje se bolje podnose, a ujedno se izbjegavaju nuspojave.

Ključne riječi: karbamazepin, okskarbazepin, epilepsija, farmakorezistencija



Ganglionic nAChR antibody positive autoimmune autonomic ganglionopathy with spontaneous recovery

Ivan Adamec¹, Luka Crnošija², Magdalena Krbot Skorić¹, Ervina Bilić^{1,2}, Mario Habek^{1,2}

ABSTRACT – We present a case of autoimmune autonomic ganglionopathy associated with ganglionic nicotinic acetylcholine receptor antibodies, orthostatic hypotension and small fiber neuropathy, notable for spontaneous recovery.

Key words: ganglionic nicotinic acetylcholine receptor antibodies, autoimmune autonomic ganglionopathy, orthostatic hypotension, hypohidrosis

INTRODUCTION

Since the identification of ganglionic nicotinic acetylcholine receptor (nAChR) antibodies, autoimmune autonomic ganglionopathy (AAG) has been established as a specific nosologic entity (1). Correlation between the antibody titer and the severity of clinical presentation has been determined (2). Its treatment is mainly based on immunotherapy, although spontaneous recovery has been proposed as well (3). We present a patient with ganglionic nAChR antibody mediated AAG associated with spontaneous recovery.

CASE REPORT

A 30-year-old male was referred for neurological examination following a one-year history of repeated falls that were occasionally accompanied by

transient loss of consciousness with rapid and complete recovery. The falls were preceded by dizziness and typically occurred on prolonged standing and walking. He experienced several cuts and bruises but had neither fractures nor other serious injuries. Besides the repeated falls that occurred almost weekly, the patient complained of a tingling sensation in his hands and feet and experienced weight loss, around 40 kg in a one-year period due to the lack of appetite. A cardiologist evaluated him; seven-day ECG monitoring, heart ultrasound and regular treadmill stress test were all normal. The patient was then referred to our department. His neurological examination was normal. A bat-

¹Zagreb University Hospital Center, Department of Neurology, Referral Center for Autonomic Nervous System Disorders, Zagreb, Croatia

²School of Medicine, University of Zagreb, Department of Neurology, Zagreb, Croatia




Fig. 1. Results of the first (blue curve) and second (red curve) tilt table test. Black vertical line represents the moment of table tilting to 70 degree angle: (a) curves of heart rate in supine position and in the tilt phase. Note a greater increase of heart rate on table tilting in the first test, a compensatory reaction due to a greater fall of blood pressure; (b) curves of systolic blood pressure in supine position and in the tilt phase. Note blood pressure level falling by more than 20 mm Hg on table tilting in the first test as opposed to a non-significant change in the second test; (c) curves of diastolic blood pressure in supine position and in the tilt phase. Note blood pressure level falling by more than 10 mm Hg on table tilting in the first test as opposed to a non-significant change in the second test.




Fig. 2. Results of Quantitative Sudomotor Axon Reflex Test. Red curve represents sweat output recorded at the forearm, blue curve at proximal leg, green curve at distal leg, and yellow curve at the foot. The area under the curve represents total sweat volume, diminished for forearm and foot recordings signifying hypohidrosis.

tery of autonomic tests was performed for quantitative assessment of adrenergic, cardiovagal and sudomotor function, and Composite Autonomic Severity Score (CASS) was applied (4). Tilt table test revealed orthostatic hypotension (OH) (Fig.1). The response of heart frequency and blood pressure values to Valsalva maneuver and deep breathing were normal. Quantitative Sudomotor Axon Reflex Test was notable for hypohidrosis of the forearm and dorsum of his hand (Fig. 2). The values of sweat output measured in microliters were as follows: medial forearm 0.282 (normal value 0.38-2.53), proximal leg 0.746 (normal value 0.58-2.64), distal leg 1.453 (normal value 0.52-2.41), and foot 0.163 (normal value 0.35-1.83). CASS score was 5 (cardiovascular 0, adrenergic 3, sudomotor 2). As the patient's falls and episodes of loss of consciousness were at that time becoming less frequent, no specific therapy was initiated. The patient was referred for electromyoneurography that was normal. Additionally, quantitative sensory testing was performed revealing A δ and C fiber neuropathy. Screening for the potential causes of small fiber neuropathy was normal consisting of the following tests: glycosylated hemoglobin, vitamin B12, folic acid, paraneoplastic antibody panel (Hu, Yo, Ri), tumor markers (carcinoembryonic antigen, CA19-9, neuron-specific enolase, cyfra 21.1, prostate-specific antigen) and immunological panel (antinuclear antigen, extractable nuclear antigen, SS-A, SS-B, angiotensin-converting enzyme). Testing for antibodies to ganglionic nAChR came

back positive with a titer of 0.333 nmol/L (normal value <0.05). One month later, he presented for follow up and at that time he had no more orthostatic symptoms, did not experience any more falls, and was without further episodes of loss of consciousness. Tilt table test was repeated and was normal (Fig. 1). On the next follow up four months later, the patient was still doing well without any symptoms. His appetite improved and he regained some of his lost weight.

DISCUSSION

We present a case of AAG associated with ganglionic nAChR, OH and small fiber neuropathy, notable for spontaneous recovery.

The pathogenicity of ganglionic nAChR antibodies has been established in animal models in which passive transfer of IgG containing ganglionic AChR antibodies induced sympathetic and parasympathetic dysfunction (5). The severity of symptoms is apparently dependent on the antibody titer. Patients with high levels of ganglionic nAChR antibodies tend to have a more pronounced dysautonomia as expressed by CASS (1). As well, the antibody level is dynamic and fall of its titer is correlated with improvement in autonomic function. The presented patient had a titer of 0.333 nmol/L, which is considered to be an intermediate level since the levels >0.5 are considered high and levels from 0.05 to 0.2 in the lower range of positive (1). This is consistent with the clinical picture as the patient's symptoms were already subsiding at the time when serology testing was performed. This particular antibody level could have been a reflection of the dynamic change and probable fall of the antibody titer. However, as the test is not readily available in our institution, we were not able to follow the exact fluctuation of the titer.

Although autonomic symptoms are the most prominent symptoms in patients with AAG, 25% of them experience sensory symptoms without obvious sensory loss (6). The presented patient had positive sensory sensations in his distal extremities and quantitative sensory testing revealed affection of small sensory fibers with normal nerve conduction studies. This is in concordance with previous pathologic studies, which found that patients with ganglionic nAChR antibodies typically had preserved large myelinated nerve fibers with various damage to the thin, unmyelinated ones (7). In this case, the patient also suffered from digestive symptoms, mainly pertaining to the upper gastrointesti-

nal tract, i.e. anorexia. This is also common in patients who are ganglionic nAChR antibody positive, as they are prone to a more widespread autonomic dysfunction than patients negative for the aforementioned antibody (8).

The presented patient initially experienced substantial orthostatic symptoms with frequent falls that considerably affected his quality of life. At that time, immunomodulatory treatment would have been doubtlessly indicated. However, since his specific diagnosis was delayed, this case actually represents a natural evolution of ganglionic nAChR antibody mediated OH. The mainstay of therapy for AAG is immunomodulation, including corticosteroids, intravenous immunoglobulins, plasma exchange for treatment of acute exacerbations, and azathioprine, rituximab and mycophenolate mofetil for maintenance therapy (6). Although this therapeutic approach seems to be efficacious, randomized controlled trials have not been performed to substantiate their effect. Specific side effects of each treatment should also be taken into consideration. The present case is notable for ganglionic nAChR antibody associated AAG with spontaneous recovery that occurred during the work up period. There have been earlier reports of spontaneous recovery of probable AAG (3,9). However, these reports date back to the era before ganglionic AChR antibodies were discovered and therefore these patients cannot be classified as definite, ganglionic AChR antibody positive AAG. To the best of our knowledge, this is the first report of serologically confirmed AAG and spontaneous recovery. This fact bears two meaningful implications. Firstly, if the symptoms in an AAG patient are not as severe and do not greatly impact the quality of life, the wait-and-see approach could be more beneficial than commencement of potentially harmful immunotherapy. Secondly, since the ganglionic nAChR titer has shown significant correlation with symptom severity, repeated antibody testing and monitoring of the titer could help reach a decision on therapy initiation in patients with moderate or fluctuating symptoms. As therapy for ganglionic nAChR autonomic neuropathy is mainly based on immunomodulatory treatment that can be accompanied by potentially serious side effects and given the fact that the titer of ganglionic nAChR antibodies can be dynamic, the question arises whether patients with mild symptoms and intermediate antibody titer should be treated immediately or would benefit from a more conservative approach. This case, presenting an AAG patient with spontaneous recovery, builds an argument for the latter.

REFERENCES


1. Vernino S, Low PA, Fealey RD, *et al.* Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. *N Engl J Med* 2000;343:847-55.
2. Klein CM, Vernino S, Lennon VA, *et al.* The spectrum of autoimmune autonomic neuropathies. *Ann Neurol* 2003;53:752-8.
3. Young RR, Asbury AK, Corbett JL, Adams RD. Pure pan-dysautonomia with recovery. Description and discussion of diagnostic criteria. *Brain* 1975;98:613-36.
4. Low PA. Composite autonomic scoring scale for laboratory quantification of generalized autonomic failure. *Mayo Clin Proc* 1993;68:748-52.
5. Vernino S, Ermilov LG, Sha L, Szurszewski JH, Low PA, Lennon VA. Passive transfer of autoimmune autonomic neuropathy to mice. *J Neurosci* 2004;24:7037-42.
6. Koike H, Watanabe H, Sobue G. The spectrum of immune-mediated autonomic neuropathies: insights from the clinicopathological features. *J Neurol Neurosurg Psychiatry* 2013;84:98-106.
7. Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Koyano S, *et al.* The spectrum of clinicopathological features in pure autonomic neuropathy. *J Neurol* 2012;259:2067-75.
8. Vernino S, Sandroni P, Singer W, Low PA. Invited Article: Autonomic ganglia: target and novel therapeutic tool. *Neurology* 2008;70:1926-32.
9. Suarez GA, Fealey RD, Camilleri M, Low PA. Idiopathic autonomic neuropathy: clinical, neurophysiologic, and follow-up studies on 27 patients. *Neurology* 1994;44:1675-82.

Address for correspondence: Ivan Adamec, MD, Department of Neurology, Zagreb University Hospital Center, Kišpatičeva 12, HR-10000 Zagreb, Croatia, e-mail: ivan.adamec@yahoo.com

Autoimuna autonomna ganglionopatija pozitivna na ganglionska nAChR protutijela sa spontanom oporavkom

SAŽETAK – Prikazuje se slučaj autoimune autonomne ganglionopatije udružene s protutijelima na ganglionske acetilkolinske nikotinske receptore, ortostatskom hipotenzijom i neuropatijom malih vlakana, s izrazito spontanom oporavkom.

Ključne riječi: ganglionski acetilkolinski nikotinski receptori, autoimuna autonomna ganglionopatija, ortostatska hipotenzija, hipohidroza



Subjects and authors index
for volume 67/2018 /
Kazalo stvari i imena
za volumen 67/2018.

Subjects index / Predmetno kazalo – vol. 67/2018.

Epilepsija – učinkovitost istodobne primjene karbamazepina i okskarbazepina u liječenju 3

Ganglionopatija autoimuna autonomna pozitivna na ganglionska nAChR protutijela sa spontanom oporavkom 11

Karbamazetip i okskarbazepin – učinkovitost istodobne primjene u liječenju epilepsije 3

Authors index / Autorsko kazalo – vol. 67/2018.

Adamec I. 11

Bilić E. 11

Bujan Kovač A. 3

Crnošija L. 11

Čajić I. 3

Đerke F. 3

Habek M. 11

Hajnšek S. 3

Krbot Skorić M. 3, 11

Nanković S. 3

Petelin Gadže Ž. 3

Poljaković Z. 3

Šulentić V. 3

Instructions to authors

NEUROLOGIA CROATICA, the official journal of the Croatian Neurological Society and Croatian Neurosurgical Society, is published twice a year by University Department of Neurology, Zagreb University Hospital Center. *Neurologia Croatica* publishes articles covering clinical neurology, basic neuroscience, and other related fields.

Neurologia Croatica publishes the following types of articles:

1. **Original contributions:** Maximum length: 3000 words, excluding tables, figure legends, and references. Total word count should be provided with each manuscript (including abstract, all text, tables, figure legends, and references).
2. **Neurological reviews:** Reviews are usually solicited by the editors, however, spontaneous submissions are also welcome. All articles and data sources reviewed should include information about the specific type of study or analysis, population, intervention, exposure, and test or outcomes. All articles or data sources should be selected systematically for inclusion in the review and critically evaluated, and the selection process should be described in the paper. Maximum length: the same as for original contributions.
3. **Case reports:** Case reports need to have important and novel learning points and report on unusual syndromes or diseases; a simple narrative or challenging patient(s) is insufficient. Maximum length 1500 words, excluding tables, figure legends, and references.
4. **Case reports of University Department of Neurology, Zagreb University Hospital Center** are solicited by the editors.
5. **Images in neurology:** This feature is intended to provide a visual image of an interesting and unique neurological observation. Images of patients along with images of diagnostic procedures performed are welcome. Maximum length: 200 words for case description, 50 words for each figure, maximum 2 references.
6. **Letters to the editor:** Letters discussing a recent *Neurologia Croatica* article are welcome. Letters should be received within 3 months of the article publication. Short comments on topical issues of public interest are also possible. Maximum length: 500 words (including all text, tables, figure legends, and references).

In addition, announcements of professional and scientific meetings will be published.

Authors are responsible for the authenticity of the data and for methodologic acceptability. Submission of a manuscript implies that it is submitted exclusively to this journal and its contents have not been published

previously except in abstract form. A statement confirming the copyright transfer to *Neurologia Croatica* signed by the first author is necessary for publication.

Author Guarantee Statement. You can download the Author Guarantee Statement form on the journal's homepage <http://www.neurologiacroatica.com/en/InstructionsForAuthors.html>. **This form should be filled in and signed by the first author of the manuscript, scanned and e-mailed together with the manuscript.** All manuscripts without signed Author Guarantee Statement will be returned to the author.

All articles are subject to review; referees are selected by the Editorial Board. Author(s) may suggest three potential referees (include names, full address, phone & fax numbers and e-mail) in the covering letter.

MANUSCRIPT PREPARATION

The form and contents of the **manuscript** should be carefully checked. All manuscripts should be written in English, with additional abstract and key words in Croatian. Manuscripts with illustrations attached and Author Guarantee Statement, prepared according to the instructions below, should be sent by mail as hard copy in triplicate, two of these without the names of authors and institutions, and by e-mail to the Editor-in-Chief's address/e-address. Authors should keep copies of the original manuscript and other related material, since the materials received will not be returned to the authors. The editor retains the right to shorten the material accepted for publication if necessary.

The complete manuscript, including text, figures, tables and references, should be typed on one side of a paper only, double-spaced, with 3 cm left margin and right margin not justified. Each paragraph should be indented by five spaces. Author should mark in the margin where figures and tables are to be inserted. Each section should start on a new page (i.e. title page, abstract, figures, tables, legends and references).

The **title page** should comprise: 1) title of paper; 2) full name of each author followed by their highest academic degrees and institutional affiliations (all institutional names should be written in English); 3) name, accurate address, phone & fax number and e-mail of the author responsible for correspondence, galley-proofs and reprints; 4) short title, not longer than 30 characters including spaces; and 5) acknowledgement of source(s) of support.

Abstracts should be no longer than 250 words. Original contributions should have structured abstracts with the following headings: objectives, methods, results and conclusions. Abstract for Neurological reviews should not be structured. Case reports should have structured

abstract with the following headings: objectives, case description, results, conclusion. Images in neurology and letters to the editor do not require an abstract. It should only present the main results and avoid general formulations and well-known facts. Three to ten key words, from Index Medicus, should be supplied in alphabetical order immediately following the abstract. Please search for the key words at the web page <http://www.ncbi.nlm.nih.gov/pubmed/>, link MeSH Database.

Text should be divided, when appropriate, into sections: Introduction, Material and Methods, Results, Discussion, and Conclusion. Scientific papers, including list of references, should not exceed 12 pages (32 lines with 60 characters each *per* page), and brief communications 3 pages.

Tables should be typed on separate sheets, not to be submitted as photographs. Illustrations should be provided unmounted, in the form and condition suitable for reproduction. Freehand drawings, raw laboratory material, e.g. strip charts, roentgenograms, etc., should be photographed in B/W. Photographs should not be larger than 20x25 cm. If the attachments are in colour (tables, photographs, etc.), the author should pay for the expenses of printing that page in agreement with the Denona Printing-House. For every photograph of a recognizable patient written permission is required. On the back of each photograph indicate its number and top of the photograph. Beside that, the set of illustrations accompanying master copy should have the name of the first author written on the back. The author(s) should be aware that the size of illustrative material may be reduced if needed. Tables and figures should be numbered in Arabic numerals in the order they are mentioned in the text. Legends for each of them should be typed separately, each legend on a separate sheet. The number of figures should not exceed 6.

List of **references** should include only those works that are cited in the text and that have been accepted for publication or already published. The list should be arranged according to the order of appearance in the text and then numbered. Several works of the same first author should be listed chronologically by the year of publication. Index Medicus abbreviations for journal names should be used.

Journals

All authors to be listed in case there are six or less:

Mubrin Z, Kos M. Assessment of dementia. Flow chart approach to clinical diagnosis. *Neurol Croat* 1992; 41: 141-156.

If the article is written by seven or more authors, only names of the first three authors should be listed, followed by "et al".:

Baršić B, Lisić M, Himbele J *et al.* Pneumococcal meningitis in the elderly. *Neurol Croat* 1992; 41: 131 - 140.

Books

Critchley M. The ventricle of memory. New York: Raven Press, 1990.

Chapter in a book

Geschwind N. The borderland of neurology and psychiatry: some common misconceptions. In: Bensom DF, Blumer D, eds. *Psychiatric aspects of neurologic disease*. New York: Grune and Stratton, 1975; 1 - 9.

Citations of works in text should be indicated by numbers in brackets.

Reprints of the published article should be ordered before publication. Thirty reprints are free of charge, and additional reprints will be provided at publishing prices.

MAILING INFORMATION

All manuscripts, with illustrations and Author Guarantee Statement enclosed should be E-MAILED as an attachment ONLY to the Editor-in-Chief to the following e-mail address: neurologiacroatica@kbc-zagreb.hr

Prof. Sanja Hajnšek, MD, PhD, Editor-in-Chief, NEUROLOGIA CROATICA, University Hospital Center Zagreb, Department of Neurology, University of Zagreb School of Medicine, Kišpatićeva 12, HR-10 000 Zagreb, Croatia; e-mail: predstojnik.nrl@kbc-zagreb.hr

Upute autorima

NEUROLOGIA CROATICA, službeno glasilo Hrvatskoga neurološkog društva i Hrvatskoga neurokirurškog društva, izdaje Klinika za neurologiju, Klinički bolnički centar Zagreb, dva puta na godinu. *Neurologia Croatica* objavljuje radove iz područja kliničke neurologije, temeljnih neuroznanosti i drugih pridruženih područja.

Neurologia Croatica objavljuje slijedeće tipove članaka:

- Izvorni znanstveni rad:** Maksimalna duljina: 3000 riječi, bez tablica, opisa slika i literature. Uza svaki tekst potrebno je navesti i ukupan broj riječi (uključujući sažetak, cijeli tekst, tablice, opise slika i literaturu).
- Neurološki pregled:** Pregledi su obično zatraženi od strane urednika, no i spontane prijave su dobrodošle. Svi pregledani članci i izvori podataka bi trebali sadržavati informaciju o specifičnoj vrsti studije ili analizi, populaciji, intervenciji, izlaganju i testu ili rezultatima. Svi članci i izvori podataka bi trebali biti sustavno odabrani za uključivanje u pregled i kritički evaluirani, te bi proces odabira trebao biti opisan u članku. Maksimalna duljina: jednako kao i za izvorne znanstvene radove.
- Izveštaji o slučaju:** Izveštaji o slučaju trebaju sadržavati bitne i nove edukacijske elemente i izvještaje o neobičnim sindromima i bolestima; jednostavan opis ili izazovni pacijent je nedovoljan. Maksimalna duljina 1500 riječi, bez tablica, opisa slika i literature.
- Izveštaji o slučajevima Klinike za neurologiju Kliničkog bolničkog centra Zagreb** će biti zatraženi od strane urednika.
- Slike u neurologiji:** Namjena ove kategorije je da prikaže vizualnu sliku zanimljivog i jedinstvenog neurološkog opažanja. Slike pacijenata zajedno sa slikama provođenja dijagnostičke procedure su dobrodošle. Maksimalna duljina: 200 riječi za opis slučaja, 50 riječi za svaku sliku, maksimalno dvije reference.
- Pisma uredniku:** Pisma koja raspravljaju o nedavnom članku objavljenom u časopisu *Neurologia Croatica* su dobrodošla. Pisma trebaju biti primljena unutar 3 mjeseca od objave članka. Kratki komentari o aktualnim pitanjima koja su od javnog interesa su također mogući. Maksimalna duljina: 500 riječi (uključujući sav tekst, opise slike i literaturu).

Uz navedene tipove objavljuju se i najave/izvješća profesionalnih i znanstvenih okupljanja.

Autorska izjava. Autorska izjava je obrazac koji možete preuzeti na svom računalu s web stranice časopisa: <http://www.neurologiacroatica.com/en/InstructionsFor-Authors.html> **Ovaj obrazac treba ispuniti i potpisati glavni autor teksta, skenirati i poslati elektroničkom poštom zajedno s tekstom.** Svi tekstovi bez potpisane autorske izjave će biti vraćeni autoru.

Svi radovi upućuju se na recenziju. Recenzente odabire Urednički odbor. Autor(i) može u svom popratnom pismu predložiti tri recenzenta (uključujući puno ime, adresu, broj telefona i telefaksa te e-mail).

PRIPREMA RUKOPISA

Radove treba poslati uz temeljitu provjeru njihova oblika i sadržaja. Svi tekstovi trebaju biti napisani na engleskom jeziku. Obvezno je priložiti i sažetak te ključne riječi na hrvatskom jeziku. Autor snosi troškove prijevoda ako je rad poslao na hrvatskom jeziku. Radove s priloženim ilustracijama i autorskom izjavom, priređene sukladno niže navedenim uputama, treba poslati u pismenom obliku u 3 primjerka, od toga dva primjerka bez imena autora i institucija, te elektroničkom poštom isključivo glavnom uredniku. Autori trebaju kod sebe zadržati primjerak rada i svih priloga, jer se zaprimljeni materijali ne vraćaju autorima. Izdavač zadržava pravo da u slučaju potrebe skрати rad prihvaćen za tisak.

Čitav rad, uključujući tekst, slike, tablice i reference, treba biti tipkan na jednoj strani papira, dvostrukim proredom, s rubom od 3 cm s lijeve strane i neporavnatim rubom s desne strane. Svaki odlomak treba biti uvučen za 5 slovnih mjesta. Na lijevom rubu autor treba označiti mjesto gdje želi umetnuti slike i tablice. Svaki dio teksta (tj. naslovnu stranicu, sažetak, slike, tablice, opise slika i reference) treba započeti na novoj stranici.

Naslovna stranica treba sadržavati slijedeće: 1. naslov rada, 2. ime i prezime svih autora te njihov najviši akademski stupanj i ustanove (imena svih ustanova trebaju biti navedena na engleskom i materinjem jeziku). 3. ime i prezime, punu adresu, broj telefona i telefaksa te e-mail autora odgovornog za korespondenciju, korekturu i otiske, 4. kratak naslov, ne duži od 30 slovnih mjesta, uključujući bjeline i 5. zahvale.

Sažetak ne treba imati više od 250 riječi. Izvorni znanstveni radovi trebaju imati strukturirani sažetak sa slijedećim naslovima: ciljevi, metode, rezultati i zaključci. Sažeci za neurološke preglede trebaju biti nestrukturirani. Izveštaji o slučajevima trebaju imati strukturirane sažetke sa slijedećim naslovima: ciljevi, opis slučaj, rezultati, zaključak. Slike u neurologiji i pisma uredniku ne zahtijevaju sažetak. U njemu valja navesti samo glavne rezultate, a izbjegavati općenite opise i poznate činjenice. Iza sažetka treba abecednim redom navesti tri do deset ključnih riječi. Molimo da ključne riječi potražite preko linka MeSH Database na web stranici <http://www.ncbi.nlm.nih.gov/pubmed/>.

Tekst rada treba, ako je prikladno, podijeliti u dijelove: Uvod, Materijal i metode, Rezultati, Rasprava i Zaključak. Znanstveni radovi, uključujući literaturu, ne bi trebali prelaziti 12 stranica (32 retka od 60 slovnih mjesta na stranici), a kratka priopćenja 3 stranice.

Tablice trebaju biti svaka na posebnoj stranici. Fotografirane tablice nisu prihvatljive. Ilustracije se prilažu u obliku prikladnom za reproduciranje. Rukom rađeni crteži, laboratorijski materijal, npr. ispisi, rentgenogrami i sl., šalju se u obliku crno-bijelih fotografija, veličine do 20x25 cm. Ako su prilozi u boji (tablice, fotografije i sl.), autor snosi trošak tiskanja te stranice u dogovoru s tiskarom "Denona". Za svaku fotografiju na kojoj se bolesnik može prepoznati potrebna je pismena privola. Na poledini svake slike valja označiti njezin broj i vrh. Usto, na primjercima ilustracija priloženim uz glavni primjerak teksta treba na poledini navesti ime prvog autora. Autori trebaju voditi računa o mogućoj potrebi smanjivanja ilustracija. Tablice i slike valja označiti arapskim brojevima redom njihova spominjanja u tekstu. Opis svake od njih treba biti tipkan na posebnom listu papira. Broj slika ne bi trebao biti veći od 6.

Literatura uključuje samo radove koji se navode u tekstu i koji su prihvaćeni za tisak ili su već objavljeni. Popis referenca treba navoditi prema redoslijedu pojavljivanja u tekstu i označiti rednim brojevima. Više radova istog autora treba navesti kronološkim redom, prema godini objavljivanja. Pri pisanju referenca treba rabiti skraćenice imena časopisa prema Indexu Medicus.

Časopisi

Treba navesti sve autore ukoliko ih je šest ili manje: Mubrin Z., Kos M. Assessment of dementia. Flow chart approach to clinical diagnosis. *Neurol Croat* 1992; 41: 141-156.

Ako citirani rad ima sedam ili više autora, treba navesti samo prva tri autora i dodati *et al.*

Baršić B, Lisić M, Himbele J *et al.* Pneumococcal meningitis in the elderly. *Neurol Croat* 1992;41:131-140.

Knjige

Critchley M. The ventricle of memory. New York: Raven Press, 1990.

Poglavlje u knjizi

Geschwind N. The borderland of neurology and psychiatry: some common misconceptions. In: Bensom DF, Blumer D, eds. *Psychiatric aspects of neurologic disease*. New York: Grune and Stratton, 1975:1-9.

U tekstu se **citirani** rad označava brojem u zagrada.

Otiske objavljenog članka treba naručiti prije tiskanja časopisa. Autori dobivaju 30 otisaka besplatno, dok se za dodatne otiske plaćaju tiskarski troškovi.

OBAVIJESTI O SLANJU RADOVA

Sve tekstove s priloženim ilustracijama i autorskom izjavom treba poslati **ELEKTRONIČKOM POŠTOM ISKLJUČIVO kao prilog** na slijedeću elektroničku adresu glavnog urednika: neurologiacroatia@kbc-zagreb.hr

Prof. dr. sc. Sanja Hajnšek, Glavna urednica, NEUROLOGIA CROATICA, Klinički bolnički centar Zagreb, Klinika za neurologiju Medicinskog fakulteta Sveučilišta u Zagrebu, Kišpatićeva 12, 10 000 Zagreb; e-mail: predstojnik.nrl@kbc-zagreb.hr

Bilješke:

Bilješke: